BGMS
Bio Green Med Solution, Inc.
There isn't enough reported data to score BGMS yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
BGMS Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Weak | |
| Unavailable |
BGMS's profitability and cash flow are currently weak. There isn't enough data to rate its revenue and balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
BGMS PE Valuation
BGMS has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
BGMS Forward outlook
There aren't enough analyst estimates for BGMS to show an outlook.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
BGMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2023 | -$7,167.83 | -$543.83 |
| Q2 2023 | -$6,948.00 | +$108.00 |
| Q1 2023 | -$7,020.00 | +$396.00 |
| Q4 2022 | -$6,840.00 | +$864.00 |
| Q3 2022 | -$6,624.00 | +$2,340.00 |
| Q2 2022 | -$7,056.00 | +$1,656.00 |
| Q1 2022 | -$7,416.00 | +$1,368.00 |
| Q4 2021 | -$7,704.00 | +$4,608.00 |
BGMS has the stronger earnings trend. Trailing diluted EPS is down 208% for BGMS versus HIMS down 257%.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
BGMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $454K | +460% |
| Q3 2025 | $81K | +710% |
| Q3 2024 | $10K | -38% |
| Q2 2024 | $4K | -99% |
BGMS's revenue has grown year over year for five quarters in a row: $454,000 last quarter, up 460% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -115% | +1110 points |
| Q2 2026 | -124% | N/A |
| Q1 2026 | -33% | N/A |
| Q4 2025 | -162% | N/A |
| Q3 2025 | -1225% | +20545 points |
| Q3 2024 | -21770% | +21011 points |
| Q2 2024 | -91100% | -89511 points |
| Q1 2024 | -15017% | N/A |
BGMS's operating margin was −115% last quarter, up 1110 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over BGMS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over BGMS on profitability, with a higher operating margin.
BGMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$287K | +$147K |
| Q2 2026 | -$352K | +$704K |
| Q1 2026 | -$279K | +$3M |
| Q3 2025 | -$434K | +$2.6M |
| Q3 2024 | -$3.1M | +$969K |
| Q4 2023 | -$3.9M | +$1.3M |
| Q3 2023 | -$4M | +$2.9M |
| Q2 2023 | -$1.3M | +$613K |
BGMS has burned cash in almost every quarter: −$951,000 over the past year, against −$8M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over BGMS on cash generation, producing positive trailing cash flow while its opponent burns cash.
BGMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +218% | +18K shares |
| 1 year | +646% | +22.7K shares |
| 3 years | +907% | +23.6K shares |
BGMS has 26,197 diluted shares, up 646% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over BGMS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
BGMS Net Leverage
BGMS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
BGMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.1 | Neutral |
| Stochastic | 31.6 | Neutral |
BGMS's weekly RSI is 32 (neutral) and its Stochastic is 32 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
BGMS PE vs Healthcare Sector
BGMS has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
BGMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.87 | 18% below |
| 20 week MA | $0.90 | 21% below |
| 50 week MA | $1.03 | 31% below |
HIMS has stronger trend alignment. BGMS is above 0 of 3 weekly averages versus HIMS above 0 of 5.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
BGMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $6.02 | $1.48 | -75% |
| 2026 YTD | $1.48 | $0.71 | -52% |
BGMS has finished every year since 2025 lower, and it's down 52% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over BGMS on returns for 2026, with the stronger performance.